Thanks, Tempe,
Nice insightful thoughts. Let’s see if we get a fair shake from FDA. I think analysts are in our corner, more than in BIIB’s, and institutional investors coming along now too it appears, slowly. This could be a landmark case for the FDA going forward - continue scratching the backs of those within the system at the expense of patients and costly economic heavy burden or finally give it over to science and the underdogs if it can be proved that the science has more merit.
Lot of integrity and future outcomes riding on the backs of the men and women in approval power to uphold their jobs and our safety and economic prudence with honor and decency. Too much to ask in a civilized, democracy?
Time will tell.
Thank you for the analysis.
Biostock